Last reviewed 2026-05-22 · How we verify

Siroquine

Johnpro Biotech, Inc. · Phase 2 active Small molecule ✓ Verified May 2026

Siroquine is a Small molecule drug developed by Johnpro Biotech, Inc.. It is currently in Phase 2 development. Also known as: JP001.

Siroquine is being studied in a Phase II/III clinical trial for the treatment of glioblastoma. The trial involves combining Siroquine with radiotherapy and the medication Temozolomide.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Siroquine
Also known as	JP001
Sponsor	Johnpro Biotech, Inc.
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Siroquine CI brief — competitive landscape report
Siroquine updates RSS · CI watch RSS
Johnpro Biotech, Inc. portfolio CI

Frequently asked questions about Siroquine

What is Siroquine?

Siroquine is a Small molecule drug developed by Johnpro Biotech, Inc..

Who makes Siroquine?

Siroquine is developed by Johnpro Biotech, Inc. (see full Johnpro Biotech, Inc. pipeline at /company/johnpro-biotech-inc).

Is Siroquine also known as anything else?

Siroquine is also known as JP001.

What development phase is Siroquine in?

Siroquine is in Phase 2.

Manufacturer: Johnpro Biotech, Inc. — full pipeline
Therapeutic area: All drugs in Other
Also known as: JP001

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing